HOME >> MEDICINE >> NEWS
Landmark Study Shows Behavioral Interventions Reduce HIV-Related Sexual Risk Behavior

The largest randomized, controlled, HIV behavioral intervention study conducted in the United States found that even among persons considered hardest to reach, such interventions can cut high risk sexual behaviors in half and more than double regular use of condoms.

The National Institute of Mental Health (NIMH) Multisite HIV Prevention Trial enrolled 3,706 men and women in 37 inner-city, community-based clinics. Those who attended HIV prevention sessions that focused on motivation and skills to reduce high-risk sexual behaviors reported significant reductions across a range of sexual risk indicators over a one-year period.

The seven-session intervention reduced the incidence of gonorrhea in men by half. Incidence of gonorrhea is an indicator of unprotected sexual behavior.

NIMH Director Steven E. Hyman, M.D., said, "Reducing high risk behaviors is still the best way to prevent new HIV infections. NIMH has identified an effective strategy that could be adopted by public health and community organizations all across America. If these behavioral changes were maintained for even one year, there would be a profound, cost-effective, public health impact in the communities that adopted this program."

Researchers in seven sites in five metropolitan areas recruited participants from three distinct populations at risk of acquiring HIV and other sexually transmitted diseases (STDs): men and women in public STD clinics and women attending public primary health care clinics. Sixty-eight percent of the participants were African American and twenty percent were Hispanic; most were single, unemployed, and treated previously for STDs, and all were at high behavioral risk for HIV. Rates of HIV infection and AIDS are higher among racial and ethnic minority populations, especially African Americans, who represented 45% of new AIDS cases in 1997. Heterosexual transmission is rising rapidly, especially among ethnic minority women. The Clinton Administrati
'"/>

Contact: Rayford Kytle
rk94a@nih.gov
301-443-4536
NIH/National Institute of Mental Health
18-Jun-1998


Page: 1 2

Related medicine news :

1. Landmark survey reveals asthma in children remains significantly out of control in the United States
2. Landmark antidepressant analysis demonstrated significant efficacy of Effexor®/Effexor XR
3. Landmark study shows coenzyme Q10 slows progressive decline in Parkinsons disease
4. Landmark XENDOS study shows Xenical prevents or delays the development of type 2 diabetes
5. Landmark study demonstrates potential for nerve regeneration treatment of stroke
6. Landmark study results published in NEJM highlight breakthrough treatment for heart failure
7. Landmark study uncovers reasons behind recurring back injury
8. Landmark clinical trial at 22 medical centers finds implanted heart pumps lengthen and improve lives of terminally ill heart failure patients
9. Landmark dialysis study findings could greatly simplify treatment of kidney disease with peritoneal dialysis
10. Landmark school-based social influences smoking-prevention program found not to work
11. U.S., British scientific societies honor penicillin as International Chemical Landmark

Post Your Comments:
(Date:6/19/2013)... The former internist for the St. Louis ... serves as director of prevention and wellness at St. ... personal encounter with a metabolic syndrome diagnosis and a ... , that he credits with sparking the paradigm-shift that ... practice. , “The average medical student gets 30 minutes ...
(Date:6/19/2013)... Recently, SoCal CEO Magazine staff was on hand ... in a series of six workshops where people with and without ... the mosaic tiles in their permanent location under the direction of ... Maxwell. , This mural project began in March of 2013 ... three years ago with the goal of promoting ...
(Date:6/19/2013)... The US Food and Drug Administration (FDA) announced ... breast implant, Mentor Worldwide’s MemoryShape™. , The FDA approved Sientra/Silimed ... FDA announced the approval of the MemoryShape™ implant on June ... in women 22 years old or older and in ... FDA’s approval comes after six years of data from 955 ...
(Date:6/19/2013)... the mantra of neurologists treating stroke victims has been "time ... room quickly to receive a drug that dissolves the stroke-causing ... brain tissue is saved or lost. , But ... of giving the intravenous drug known as a tissue ... ischemic (clot-caused), stroke, the most common type of stroke. ...
(Date:6/19/2013)... fact that the incidence of cancer is many fold ... still have an inadequate understanding on how best to ... patients are occasionally included in clinical trials, those elderly ... elderly patients. Thus, the broader elderly patient population is ... in the Elderly Task Force is now starting a ...
Breaking Medicine News(10 mins):Health News:Plant-based Nutrition is Key to Health Transformation of St. Luke’s Hospital Director of Prevention and Wellness 2Health News:Plant-based Nutrition is Key to Health Transformation of St. Luke’s Hospital Director of Prevention and Wellness 3Health News:Arc Creates Huge Mosaic Mural to Highlight the Need for Greater Respect of People with Disabilities 2Health News:FDA Approved Mentor® MemoryShape™ Breast Implants Now Offered to Patients at Swan Center for Plastic Surgery 2Health News:Timely treatment after stroke is crucial, UCLA researchers report 2Health News:Timely treatment after stroke is crucial, UCLA researchers report 3Health News:EORTC study opens for elderly patients with HER-2 positive metastatic breast cancer 2
(Date:6/19/2013)... June 19, 2013   Life Technologies Corporation ... licensing agreement granting Suzhou Ribo Life Sciences (Ribo) ... therapeutics in China using ... proprietary siRNA molecules in combination with Invivofectamine® Rx ... human diseases with high unmet medical need in ...
(Date:6/19/2013)... 19. Juni 2013 Specialty ... der Entwicklung von SCS microRESIST™, einer ... der Beschichtung mit Parylene gelungen ist. ... biokompatiblem Parylene mit antimikrobiellen Eigenschaften und ... Mikroorganismen auf beschichteten medizinischen Geräten. ...
(Date:6/18/2013)... 18, 2013  Intercept Pharmaceuticals, Inc.  (NASDAQ: ... the development and commercialization of novel bile acid therapeutics ... of an underwritten public offering of 1,730,000 shares of ... $33.01 per share.  In addition, Intercept has granted the ... additional 259,500 shares of common stock. All ...
Breaking Medicine Technology:Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 2Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 3Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 4Specialty Coating Systems gibt die Einführung einer neuen antimikrobiellen Parylene-Technologie bekannt 2Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2
Cached News: